-
A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer
This is a phase 1b study testing whether the study medicine ZEN003694 (BET bromodomain inhibitor), together with pembrolizumab (immunotherapy) and nab-paclitaxel (standard chemotherapy), works well ...
-
DAY101-002; LOGGIC/FIREFLY-2: A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy.
The study is also being done to learn more about how the study drug is absorbed (taken up in the body), metabolized (broken down by ...
-
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC Lenalidomide and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy.
This is a phase 3 study to test medicines named Teclistamab (Tec-DR) and Talquetamabin (Tal-DR) together with standard treatment called Daratumumab SC, Lenalidomide, and Dexamethasone ...
-
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
This study is an expanded access protocol (EAP), meaning it is testing the safety and effectiveness of a medicine called nonconforming lisocabtagene maraleucel (a batch ...
-
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy
This study looks at how safe and effective a medicine called Tag is when combined with Ven and Aza for people with CD123+ acute myeloid ...
-
A PHASE I FIRST-IN-HUMAN OPEN-LABELTRIALTO INVESTIGATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0500 A HUMANIZE GPRC5D-BCMA-CD3 TRISPECIFIC ANTIBODY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
This is a clinical trial that aims to test the effectiveness and how the body processes a drug called SIM0500 in adult patients with relapsed ...
-
A Phase 1/2 Multicenter Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination with Abemaciclib in Patients with Solid Tumors with MTAP Loss
This study is testing a new medicine, TNG456, alone and with another medicine called Abemaciclib, to find the dose that works well and has fewer ...
-
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
This study is testing whether receiving medicine called cemiplimab (PD-L1 antibody), before surgery (neoadjuvant immunotherapy), is more effective than standard surgery for patients with resectable ...
-
A Multi-center Randomized Open-label Parallel-group Phase 2 Study to Evaluate the Efficacy and Safety of VS-101 in Combination with Chemoradiotherapy (CRT) in Patients with Head and Neck Cancer
This is a Phase 2 study testing the study medicine VS-101 (an oral radiosensitizer) in combination with Chemoradiotherapy (CRT) in patients with head and neck ...
-
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) A COG Groupwide Phase 3 Study
This is a phase III study using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the ...